A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 734-738

  Tol, J ^a   Koopman, M ^a   Rodenburg, C J ^b   Cats, A ^c   Creemers, G J ^e   Schrama, J G ^f   Erdkamp, F L G ^g   Vos, A H ^h   Mol, L ⁱ   Antonini, N F ^d   Punt, C J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d Department of Biometrics ^*  (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f Infection and Immunology   (Netherlands)

^g Sittard Geleen Heerlen   (Netherlands)

^h BERNHOVEN HOSPITAL   (Netherlands)

ⁱ Integraal Kankercentrum Oost   (Netherlands)

Author keywords

Advanced colorectal cancer; Bevacizumab; Cetuximab; Chemotherapy; Interim analysis; Safety

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NETHERLANDS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ERUPTIONS; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; ORGANOPLATINUM COMPOUNDS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 41549167668     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm607     Document Type: Article

References (18)

1. Punt CJ. New options and old dilemmas in the treatment of patents with advanced colorectal cancer. Ann Oncol 2004; 15(10): 1453-1459.
2. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 2007; 370(9582):135-142.
3. Tol J, Punt CJA Targeted therapy in advanced colorectal cancer, an update. Targeted Oncology 2007; 2(3): 165-172.
4. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-345.
5. Jonker DJ, O'Callaghan CJ, Karapetis CS at al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357(20): 2040-2048.
6. van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5FU/LV with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL study. Proc Am Soc Clin Oncol 2007; 25:164S [Abstr 4000].
7. Seltz LB, Lenz HJ, Kindler HL et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007; 25(29): 4557-4561.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19(21): 4097-4106.
9. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX 4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol GI Cancer Symp 2007; [Abstr 238].
10. Diaz-Rubio E, Tabemero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-Infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25(27): 4224-4230.
11. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AID Colorectal Study Group. J Clin Oncol 2007; 25(27): 4217-443.
12. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg. Oncol 2007; 14(6): 1860-1869.
13. Scappaticcl FA, Skillings JR, Holden SN et al. Arterial thromboemboiic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99(6): 1232-1239.
14. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
15. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The additional of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23(16): 3706-3712.
16. Schrag Q, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97(16): 1221-1224.
17. Tejpar S, Piessevaux H, Claes K et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. Lancet Oncol 2007; 8(5): 387-394.
18. Hecht JR, Chidiac T, Mitchell E. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC) Proceedings of the 9th World Congress on Gastrointestinal Cancer. Ann Oncol 2007; 18: Vii21 (Abstr 0-0033).